At one time I did take a speculative position in NFLD. The story was so compelling. After a few months of seeing no action other than an occassional press release from the company, I began to wonder why, if there was merit to the company's product and story, and we were at war, weren't the US Gov. and Pentagon all over them?
It was a gut reaction, but the scenario just didn't feel right.
I sold to find greener pastures. Sure glad I did, but have nothing more than my "gut" to thank.

I remember researching this company while travelling on business. The bits and pieces of information I sent, IMO did not make this stock worthy of purchase except with casino money.

The project was great reinforcement (after todays debacle) that traders need to investigate and have standards for the paper they buy and sell.

No question that one day a human blood substitute will be perfected and for that company and it's investors the profit will be handsome.

However after following the Hemosol (HML-T) story years back - cb is right about "casino money".

If you really want to do some interesting research, please look at how much investors have wasted in the last 25yrs chasing a blood substitute. IF you don't want to be added to that list do your reseach and please play close attention to the raw material requirements for this product. (hint)

Gotta listen to a guy whose handle is..blood.

Bill,

When your Northfield item appeared I recall writing to you suggesting that there was something wonky about their needing to use questionable and controversial practices in emergency rooms to get their product used (tested?) without patient consent when they could have gone to the Dept of Defense and found ways to have it used on the abundant resource of wounded troops in Iraq. Surely Mr Rumsfeld would have obliged. The whole thing smelled and looked bloody bad. Hopefully, readers didn't get taken down by this one as a result of a lack of open dialogue and and the decision to block comment at your site.

Blech, Hemosol. Any company that builds a $90 million processing plant (the "Ferrari of plants") next to a golf course for a product that causes "adverse effects" i.e. "cardiac arrest" is bound to have troubles.

I wonder if it is time to sell my shares yet? :(

http://www.noblood.org/news-hot-topics-such-hepatitis-c-sars-aids/1285-hemosol-once-seemed-doomed-but-strategy-shift-may-stop-bleeding.html

(I don't think their strategy shift worked out.)

I'm going to go buy some tulip bulbs...

Off topic but since the Bull Board isn't up yet today, check this out:

http://biz.yahoo.com/ap/061220/guyana_iamgold.html?.v=1

The Chineese continue to be willing buyers of solid assets. How long before the Royalty Trusts are gobbled up by them due to Flaherty's missteps and lack of forethought?

Bill, you ask if the traders were front running. When they short shares they will do so to the maximum. That is until there are none left to sell short. When this occurs the fee to borrow stock can exceed forty percent. DataExplorers charges for a complete list of stocks and lending revenue but they make a list of the top ten earners available for free. Go to www.dataexplorers.co.uk, click on performanceexplorer, click on SUMMARY STATISTICS, register for free, log in, scroll down to Equities by Fee. Northfield made the list in October. They debuted at fifth or sixth depending upon whether you consider FFH on Toronto and FFH on NYSE to be one stock or two.

The point of selling short to someone who lends for a high fee from someone who lends for a high fee, (the stock is going in circles)is to make as big a bet as possible on a company with a small float.